HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Daratumumab, Cytoxan, Dex and Velcade for Newly Diagnosed and Relapsed Myeloma
Posted: Jan 08, 2017
Clinical Trial: Daratumumab, Cytoxan, Dex and Velcade for Newly Diagnosed and Relapsed Myeloma image

Daratumumab is now being used in many clinical trials in many different combinations. Because of its success in past clinical trials, it is moving to earlier use (in studies) for both newly diagnosed patients and at first relapse. According to Torben Plesner, MD in a recent Myeloma Crowd Radio show , daratumumab shows interesting results when effectively combined with cyclophosphamide (Cytoxan). This study will evaluate responses (complete response and very good partial response) for newly diagnosed and relapsed patients. The study combination will include four drugs: daratumumab, cyclophosphamide, dexamethasone and bortezomib. The study is open in 32 locations. To learn more, click the button below. Dara with CyborD Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube